Growth Hormone Tumor Histological Subtypes Predict Response to Surgical and Medical Therapy

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 Aug 18

PMID 25129651

Citations 50

Authors

Katja Kiseljak-Vassiliades

Nichole E Carlson

Manuel T Borges

B K Kleinschmidt-DeMasters

Kevin O Lillehei

Janice M Kerr

Margaret E Wierman

Affiliations

Soon will be listed here.

Abstract

Growth hormone (GH) pituitary tumors are associated with significant morbidity and mortality. Current treatments, including surgery and medical therapy with somatostatin analogs (SSA), dopamine agonists and/or a GH receptor antagonist, result in disease remission in approximately half of patients. Predictors of GH tumor response to different therapies have been incompletely defined based on histologic subtype, particularly densely (DG) versus sparsely (SG) granulated adenomas. The aim of this study was to examine our own institutional experience with GH adenomas and correlate how subtype related to clinical parameters as well as response to surgery and medical therapies. A retrospective chart review of 101 acromegalic patients operated by a single neurosurgeon was performed. Clinical data were correlated with histologic subtype and disease control, as defined by IGF-1 levels, and random growth hormone levels in response to surgery and/or medical therapies. SG tumors, compared to DG, occurred in younger patients (p = 0.0010), were 3-fold larger (p = 0.0030) but showed no differences in tumor-invasion characteristics (p = 0.12). DG tumors had a higher rate of remission in response to surgery compared to SG, 65.7 vs. 14.3 % (p < 0.0001), as well as to medical therapy with SSAs (68.8 % for DG vs. 28.6 % for SG tumors; p = 0.028). SG tumors not controlled with SSAs consistently responded to a switch to, or addition of, a GH receptor antagonist. Histological GH tumor subtyping implicates a different clinical phenotype and biologic behavior, and provides prognostic significance for surgical success and response to medical therapies.

Citing Articles

A single-center prospective study evaluating the relationship of tumor consistency on remission in acromegaly patients.

Yilmaz E, Ozturk S, Uzuner A, Yildirim P, Emengen A, Gokbel A Sci Rep. 2025; 15(1):868.

PMID: 39757249 PMC: 11701084. DOI: 10.1038/s41598-025-85331-5.

Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly.

Gasco V, Prencipe N, Cuboni D, Varaldo E, Sibilla M, Aversa L J Endocrinol Invest. 2024; .

PMID: 39739300 DOI: 10.1007/s40618-024-02519-8.

Growth Hormone-Secreting Pituitary Adenoma: Dura Mater Invasion Is Not a Predictor of Acromegaly Persistence After Trans-Sphenoidal Surgery.

Prencipe N, Varaldo E, Di Perna G, Bertero L, Berton A, Baldassarre B J Clin Med. 2024; 13(23).

PMID: 39685770 PMC: 11642402. DOI: 10.3390/jcm13237312.

Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern.

Kim K, Kim Y, Kim S, Moon J, Kim E, Lee E Front Oncol. 2024; 14:1423606.

PMID: 39139281 PMC: 11319302. DOI: 10.3389/fonc.2024.1423606.

Predictors of Remission of Acromegaly following Surgical Treatment in Growth Hormone-Secreting Pituitary Adenoma.

Konar S, Yeole U, Shukla D, Bhat D, Sadashiva N, Devi B J Neurol Surg B Skull Base. 2024; 85(3):261-266.

PMID: 38721370 PMC: 11076092. DOI: 10.1055/s-0043-57233.

References

Neumann P, Goldman J, Horoupian D, Hess M . Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments. Arch Pathol Lab Med. 1985; 109(6):505-8. View

Lely A, Biller B, Brue T, Buchfelder M, Ghigo E, Gomez R . Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012; 97(5):1589-97. DOI: 10.1210/jc.2011-2508. View

Lekva T, Berg J, Fougner S, Olstad O, Ueland T, Bollerslev J . Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J Clin Endocrinol Metab. 2012; 97(8):E1506-14. DOI: 10.1210/jc.2012-1760. View

Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T . Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J. 2011; 59(3):221-8. DOI: 10.1507/endocrj.ej11-0177. View

Mayr B, Buslei R, Theodoropoulou M, Stalla G, Buchfelder M, Schofl C . Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol. 2013; 169(4):391-400. DOI: 10.1530/EJE-13-0134. View

Clemmons D, Chihara K, Freda P, Ho K, Klibanski A, Melmed S . Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab. 2003; 88(10):4759-67. DOI: 10.1210/jc.2003-030518. View

Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O . Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol. 2013; 168(4):491-9. DOI: 10.1530/EJE-12-0864. View

Kasuki L, Vieira Neto L, Wildemberg L, Colli L, de Castro M, Takiya C . AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012; 19(3):L25-9. DOI: 10.1530/ERC-12-0020. View

Karantza V . Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2010; 30(2):127-38. PMC: 3155291. DOI: 10.1038/onc.2010.456. View

10.

Shimon I, Cohen Z, Ram Z, Hadani M . Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery. 2001; 48(6):1239-43; discussion 1244-5. DOI: 10.1097/00006123-200106000-00008. View

11.

Yamada S, Aiba T, Sano T, Kovacs K, SHISHIBA Y, Sawano S . Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery. 1993; 33(1):20-7. DOI: 10.1227/00006123-199307000-00003. View

12.

Lundin P, Pedersen F . Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr. 1992; 16(4):519-28. DOI: 10.1097/00004728-199207000-00004. View

13.

Kasuki L, Vieira Neto L, Gadelha M . Cabergoline treatment in acromegaly: cons. Endocrine. 2014; 46(2):220-5. DOI: 10.1007/s12020-014-0183-4. View

14.

Carmichael J, Bonert V, Mirocha J, Melmed S . The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2008; 94(2):523-7. DOI: 10.1210/jc.2008-1371. View

15.

Sandret L, Maison P, Chanson P . Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011; 96(5):1327-35. DOI: 10.1210/jc.2010-2443. View

16.

Mercado M, Borges F, Bouterfa H, Chang T, Chervin A, Farrall A . A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007; 66(6):859-68. PMC: 1974838. DOI: 10.1111/j.1365-2265.2007.02825.x. View

17.

Kiseljak-Vassiliades K, Shafi S, Kerr J, Phang T, Kleinschmidt-DeMasters B, Wierman M . Clinical implications of growth hormone-secreting tumor subtypes. Endocrine. 2012; 42(1):18-28. DOI: 10.1007/s12020-012-9660-9. View

18.

Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A . Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol. 2010; 163(4):531-9. DOI: 10.1530/EJE-10-0586. View

19.

Asa S, Ezzat S . The pathogenesis of pituitary tumors. Annu Rev Pathol. 2009; 4:97-126. DOI: 10.1146/annurev.pathol.4.110807.092259. View

20.

Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K . The German ACROSTUDY: past and present. Eur J Endocrinol. 2009; 161 Suppl 1:S3-S10. DOI: 10.1530/EJE-09-0350. View